Author/treatment type

Follow up outcomes measures/radiographs

Balke et al. [19] /

Bisphosphonates

Post treatment clinical outcomes were heterogeneous but included: stable tumor size (n = 11), decrease in tumor size (n = 1), decrease in pain (n = 8), no further recurrence (n = 12), stable lung metastases (n = 9), disease progression (n = 3), recurrence (n = 1) Radiographic: Metastases did not increase in size or number when assessed by lung CT or X-ray in patients during the follow-up period.

Chawla et al. [18] / RANK Ligand Antibody

Cohort 1—Clinical benefit was seen in 67 of 169 (41%) patients and included pain reduction in 28%, improved mobility in 22%, and improved function in 19%. Cohort 2—Clinical benefit was seen in 61 of 100 (61%) patients and included pain reduction in 50%, improved mobility in 33%, and improved function in 23%. Radiographic: An objective radiographic complete or partial response was noted in 136 of 187 (72%) analyzed patients. By modified RECIST criteria, 47 of 187 (25%) had responses. The median time to radiographic response was 3.1 months and this response was maintained for at least 24 weeks in 76 of 111 (67%) patients analyzed with at additional time points.